NASDAQ:PHIO

Phio Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy PHIO

*Your capital is at risk

$1.04

-0.0100 (-0.95%)

At Close: Jun 23, 2026

Phio Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 98.55. In total, the insiders bought 1.26M and sold 18.68K PHIO shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	98.55
● Buy	1.26M shares
● Sell	18.68K shares
84% Buy Activity Moderate Negative Correlation
Buy Signal High Confidence Feb 05, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 98.55. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (84% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 05, 2026 Buy	Common Stock, $.0001 par value A-Award	Bitterman Robert J Chairman, Pres. & CEO	CEO / President	120 000 Value: $102.8K
Feb 05, 2026 Buy	Common Stock, $.0001 par value A-Award	Carson Lisa Cabott Chief Financial Officer	C-Suite Officer	47 000 Value: $40.3K
Feb 05, 2026 Buy	Common Stock, $.0001 par value A-Award	Freeman Jonathan E Director	Director	16 600 Value: $14.2K
Feb 05, 2026 Buy	Common Stock, $.0001 par value A-Award	Lockshin Curtis Director	Director	16 600 Value: $14.2K
Feb 05, 2026 Buy	Common Stock, $.0001 par value A-Award	Deming David H Director	Director	23 800 Value: $20.4K
Feb 05, 2026 Buy	Common Stock, $.0001 par value A-Award	Bradford Patricia A Director	Director	18 500 Value: $15.9K
Dec 31, 2025 Buy	Common Stock, $.0001 par value P-Purchase	Bitterman Robert J Chairman, Pres. & CEO	CEO / President	5 000 Value: $5K
Dec 23, 2025 Buy	Common Stock, $.0001 par value P-Purchase	Bitterman Robert J Chairman, Pres. & CEO	CEO / President	5 000 Value: $5K
Nov 21, 2025 Buy	Common Stock, $.0001 par value P-Purchase	Bitterman Robert J Chairman, Pres. & CEO	CEO / President	5 000 Value: $6K
Nov 18, 2025 Buy	Common Stock, $.0001 par value P-Purchase	Bitterman Robert J Chairman, Pres. & CEO	CEO / President	5 000 Value: $6K
Sep 11, 2025 Buy	Common Stock, $.0001 par value A-Award	Ferrara Robert L Director	Director	23 100 Value: $53.6K
Sep 11, 2025 Buy	Common Stock, $.0001 par value A-Award	Deming David H Director	Director	14 000 Value: $32.5K
Sep 11, 2025 Buy	Common Stock, $.0001 par value A-Award	Lockshin Curtis Director	Director	16 200 Value: $37.6K
Sep 11, 2025 Buy	Common Stock, $.0001 par value A-Award	Freeman Jonathan E Director	Director	14 700 Value: $34.1K
Sep 11, 2025 Buy	Common Stock, $.0001 par value A-Award	Ferrara Robert L Director	Director	23 000 Value: $53.4K
Sep 11, 2025 Buy	Common Stock, $.0001 par value A-Award	Carson Lisa Cabott Vp, Finance And Administration	Officer	47 000 Value: $109.0K
Sep 11, 2025 Buy	Common Stock, $.0001 par value A-Award	Bradford Patricia A Director	Director	18 800 Value: $43.6K
Sep 11, 2025 Buy	Common Stock, $.0001 par value A-Award	Bitterman Robert J Chairman, Pres. & CEO	CEO / President	250 000 Value: $580.0K
Sep 11, 2025 Sell	Common Stock, $.0001 par value F-InKind	Bitterman Robert J Chairman, Pres. & CEO	CEO / President	4 111 Value: $10K
Sep 11, 2025 Sell	Common Stock, $.0001 par value F-InKind	Bitterman Robert J Chairman, Pres. & CEO	CEO / President	4 111 Value: $10K
Sep 11, 2025 Buy	Common Stock, $.0001 par value A-Award	Bitterman Robert J Chairman, Pres. & CEO	CEO / President	250 000 Value: $580.0K
Sep 11, 2025 Buy	Common Stock, $.0001 par value A-Award	Bradford Patricia A Director	Director	18 800 Value: $43.6K
Sep 11, 2025 Buy	Common Stock, $.0001 par value A-Award	Carson Lisa Cabott Vp, Finance And Administration	Officer	47 000 Value: $109.0K
Sep 11, 2025 Buy	Common Stock, $.0001 par value A-Award	Ferrara Robert L Director	Director	23 000 Value: $53.4K
Sep 11, 2025 Buy	Common Stock, $.0001 par value A-Award	Freeman Jonathan E Director	Director	14 700 Value: $34.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT PHIO PHARMACEUTICALS CORP.

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic pr...

Read Full Profile Here